Niv releases the inhibitory state of the T lymphocytes by binding to the PD-1 molecule expressed by the T lymphocytes; which in turn blocks its binding to tumor cells expressing its ligand PD-L1, and thus reinstates the antitumor effect of the T lymphocytes [41,42] (Figure 10). Here, PDCD1 is linked to neoplasm.